Chinese authorities approved Chongqing Genrix Biopharmaceutical's (SHA:688443) clinical trial for its GR1802 injection for seasonal allergic rhinitis, according to a Wednesday filing with the Shanghai bourse.
The trial is intended for allergic rhinitis in adolescents, the filing said.
The drug is also indicated for atopic dermatitis in adults, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, and allergic rhinitis, among others, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments